| Popis: |
Despite great efforts in developing novel screening, diagnosis and therapeutic strategies, the incidence and mortality of ovarian cancer have not significantly changed in the last 30 years. [1] It remains the leading cause of death from gynecologic malignancy with a lifetime proba‐ bility of developing the disease of 1 in 59.[1] Worldwide, approximately 200.000 women are annually diagnosed with ovarian cancer,[2] and almost 70% of them will be diagnosed at ad‐ vanced stage disease.[3] With current treatment modalities, the 5-year survival rate ranges from 80–95% for those with organ-confined or early stage disease (International Federation of Gynecology and Obstetrics (FIGO) stage I-II); to 30 – 40% for those women with advanced dis‐ ease, FIGO stage III-IV. Thus, ovarian cancer is a challenging and complex malignancy.[4] |
